Systemic sclerosis & Raynaud's
Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease
Authors' conclusion
These findings illustrate the progressive nature of SSc-ILD and support the efficacy of nintedanib in slowing decline in lung function over the long term.
Study context
- Population
- Patients with SSc-ILD in the SENSCIS and SENSCIS-ON trials
- Participants
- 197 vs 231
- Comparison
- Continued nintedanib vs switch from placebo to nintedanib
- Nintedanibn = 197
- Placebon = 231reference
- Primary endpoint
- Trajectory of forced vital capacity (FVC) (mean decline)
- Follow-up
- 52 weeks
Methodological detailsoff-treatment period ≤ 12 weeks between trials
- Off-treatment period ≤ 12 weeks between trials
Primary result
As reported in the abstract
Mean decline in FVC, 52 weeks before last on-treatment measurement in SENSCIS
Nintedanib
- 41.5
mean · mL
Placebo
- 96.8
mean · mL
Further findings
Mean -, mL
| Outcome | Nintedanib | Placebo |
|---|---|---|
| Mean decline in FVC, baseline to week 52 of SENSCIS-ON (all on nintedanib)Placebo group received nintedanib in SENSCIS-ON | 58.3 | 42.8 |
Original publication
Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease. Arthritis Res Ther. Published 21 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →